open access

Vol 9, No 6 (2005)
Kontrowersje w nadciśnieniu tętniczym
Published online: 2005-12-13
Get Citation

The regression of vascular changes in hypertension - calcium channel blocker or angiotensin-converting enzyme inhibitor?

Danuta Czarnecka, Katarzyna Styczkiewicz
Nadciśnienie tętnicze 2005;9(6):489-498.

open access

Vol 9, No 6 (2005)
Kontrowersje w nadciśnieniu tętniczym
Published online: 2005-12-13

Abstract

Recent advances in the understanding of vascular disease genesis suggest that atherosclerosis and hypertension are associated with changes in structural and functional parameters of vascular wall. Antihypertensive treatment decreases the rate of hypertension-related cardiovascular events and also reduces the development of atherosclerosis. Endothelial dysfunction is the early event that allows penetration of lipids and inflammatory cells into the arterial wall, contributing to the development of the atherosclerotic lesion. Agents that restore endothelial function have beneficial anti-atherogenic activities and can improve cardiovascular outcomes. This has been observed with angiotensin- converting enzyme inhibitors (ACEI) and certain dihydropyridine-type calcium channel blockers (CCB). Moreover, recent clinical trials have provided evidence that these classes of drugs can remodel the arterial smooth muscle cell membrane and inhibit the progression of atherosclerotic disease. There is evidence that ACEI and CCB exert an antiatherosclerotic action that is at least partly independent of the blood pressure-decreasing effect. An important question is whether ACEI and CCB - considered as the most effective antihypertensive agents with anti-atherogenic activities - affect atherosclerosis to a similar extent. Which therapy is more effective in reducing the progression of atherosclerotic lesions? This article summarizes our current thinking on the role of ACEI and CCB on atheroprotection in hypertensive patients. There are also presented numerous trials measuring the effects of ACEI and CCB on vascular wall characteristics especially on the intima-media thickness regarded as an early sign of atherosclerosis and sensitive predictor of future cardiovascular complications.

Abstract

Recent advances in the understanding of vascular disease genesis suggest that atherosclerosis and hypertension are associated with changes in structural and functional parameters of vascular wall. Antihypertensive treatment decreases the rate of hypertension-related cardiovascular events and also reduces the development of atherosclerosis. Endothelial dysfunction is the early event that allows penetration of lipids and inflammatory cells into the arterial wall, contributing to the development of the atherosclerotic lesion. Agents that restore endothelial function have beneficial anti-atherogenic activities and can improve cardiovascular outcomes. This has been observed with angiotensin- converting enzyme inhibitors (ACEI) and certain dihydropyridine-type calcium channel blockers (CCB). Moreover, recent clinical trials have provided evidence that these classes of drugs can remodel the arterial smooth muscle cell membrane and inhibit the progression of atherosclerotic disease. There is evidence that ACEI and CCB exert an antiatherosclerotic action that is at least partly independent of the blood pressure-decreasing effect. An important question is whether ACEI and CCB - considered as the most effective antihypertensive agents with anti-atherogenic activities - affect atherosclerosis to a similar extent. Which therapy is more effective in reducing the progression of atherosclerotic lesions? This article summarizes our current thinking on the role of ACEI and CCB on atheroprotection in hypertensive patients. There are also presented numerous trials measuring the effects of ACEI and CCB on vascular wall characteristics especially on the intima-media thickness regarded as an early sign of atherosclerosis and sensitive predictor of future cardiovascular complications.
Get Citation

Keywords

atherosclerosis; calcium channel blocker; angiotensin-converting enzyme inhibitor

About this article
Title

The regression of vascular changes in hypertension - calcium channel blocker or angiotensin-converting enzyme inhibitor?

Journal

Arterial Hypertension

Issue

Vol 9, No 6 (2005)

Pages

489-498

Published online

2005-12-13

Bibliographic record

Nadciśnienie tętnicze 2005;9(6):489-498.

Keywords

atherosclerosis
calcium channel blocker
angiotensin-converting enzyme inhibitor

Authors

Danuta Czarnecka
Katarzyna Styczkiewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl